Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients

<b>Background:</b> Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-Biosimilar) in 2021. Hence...

Full description

Saved in:
Bibliographic Details
Main Authors: Tamather Almandeel, Mansoor Ahmed Khan, Ashwag Algethami, Mashael S. Alaboud, Munirah A. Alkathiri, Mohammed Aseeri, Ahmed Absi, Mubarak Almansour, Abdullah Alotaibi
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Pharmacy
Subjects:
oncology biosimilars
rituximab biosimilar
extrapolation
pharmacovigilance
real-world evidence
Online Access:https://www.mdpi.com/2226-4787/13/3/83
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items